Geode Capital Management LLC lessened its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 5.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,374,745 shares of the biotechnology company's stock after selling 450,186 shares during the quarter. Geode Capital Management LLC owned 1.23% of OPKO Health worth $12,481,000 as of its most recent filing with the SEC.
Other hedge funds have also recently bought and sold shares of the company. CIBC Asset Management Inc increased its position in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 8,978 shares in the last quarter. PFG Investments LLC increased its holdings in OPKO Health by 2.5% in the 2nd quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company's stock valued at $1,201,000 after purchasing an additional 23,700 shares in the last quarter. American Century Companies Inc. acquired a new stake in OPKO Health in the 2nd quarter valued at $112,000. Y.D. More Investments Ltd purchased a new position in OPKO Health in the second quarter valued at about $1,840,000. Finally, Hollencrest Capital Management lifted its stake in shares of OPKO Health by 14.0% during the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 11,020 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company's stock.
OPKO Health Price Performance
OPK remained flat at $1.47 on Tuesday. The company had a trading volume of 2,964,732 shares, compared to its average volume of 6,662,167. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.76. The firm has a 50-day moving average of $1.55 and a 200 day moving average of $1.49. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm has a market cap of $1.00 billion, a PE ratio of -7.74 and a beta of 1.62.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on OPK shares. Piper Sandler reiterated an "overweight" rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. Barrington Research reaffirmed an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. StockNews.com cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Thursday, December 26th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th.
Get Our Latest Stock Report on OPK
Insider Buying and Selling at OPKO Health
In related news, CEO Phillip Md Et Al Frost bought 280,183 shares of the business's stock in a transaction dated Friday, November 8th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $420,274.50. Following the purchase, the chief executive officer now owns 211,512,405 shares in the company, valued at $317,268,607.50. This trade represents a 0.13 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have acquired a total of 1,304,255 shares of company stock valued at $2,024,605 in the last three months. Corporate insiders own 47.26% of the company's stock.
About OPKO Health
(
Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Featured Stories
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
